TOKYO, JAPAN – August 25, 2025 – Terumo Corporation (TSE: 4543) has signed a definitive agreement to acquire UK-based OrganOx Limited for approximately USD 1.5 billion, marking its strategic entry into the organ transplantation sector. The all-shares acquisition, expected to close following U.S. regulatory approvals, will make OrganOx a wholly owned subsidiary of Terumo.
The deal positions Terumo to diversify its portfolio beyond cardiovascular, vascular access, and infusion systems into organ preservation, a fast-emerging medical technology space with unmet global demand. OrganOx, founded in 2008 as a University of Oxford spin-off, is a recognized leader in Normothermic Machine Perfusion (NMP) devices that extend organ viability and improve transplant outcomes. Terumo previously made a venture investment in OrganOx in March 2025 and is now fully integrating the company as a growth driver for the medium to long term.
Why This Acquisition Matters for Life Science Industry:
The acquisition builds on Terumo’s March 2025 investment via its corporate venture arm, Terumo Ventures. By integrating OrganOx’s advanced technology, Terumo aims to:
- Broaden access to life-saving transplants,
- Improve organ utilization, including from “marginal donors”
- Reduce the burden on healthcare systems by minimizing emergency and nighttime procedures
Science Significance
OrganOx’s NMP platform enables donor organs to be preserved at near-body temperature with oxygen- and nutrient-rich perfusate, allowing real-time monitoring of viability. This represents a major leap beyond cold storage methods, potentially increasing organ utilization rates, improving transplant outcomes, and reducing the number of discarded donor organs. Over 6,000 liver transplants worldwide have already benefited from OrganOx’s flagship device, metra.
Regulatory Significance
Advertisement
OrganOx’s metra device has received regulatory approvals across the U.S., EU, UK, Canada, and Australia, and is fully commercialized in these markets. With Terumo’s global infrastructure, the technology is poised for accelerated adoption and expanded regulatory harmonization. The acquisition further aligns with regulatory efforts to support advanced medical technologies that improve patient safety, optimize organ quality assessment, and reduce post-transplant complications.
Business Significance
The acquisition strengthens Terumo’s portfolio by adding a high-growth segment with medium- to long-term potential. OrganOx reported £55.2 million in net sales in 2024, a nearly threefold increase from 2023, signaling robust market demand. Beyond liver devices, OrganOx is developing kidney preservation systems, targeting commercialization by 2030, potentially unlocking another multi-billion-dollar market. For Terumo, this represents both diversification and a new growth driver.
Patients’ Significance
For patients, this deal promises greater access to life-saving transplants. By extending organ viability and enabling the use of “marginal donor” organs—those traditionally deemed unsuitable due to age, pre-existing conditions, or cardiac death—the technology could dramatically shorten waiting lists. In the U.S. alone, around 6,000 patients die each year while awaiting a transplant. Terumo and OrganOx’s combined expertise directly addresses this urgent need.
Policy Significance
The acquisition resonates with public health policy priorities globally, where governments and health agencies are working to improve transplant infrastructure and outcomes. Broader adoption of NMP devices could influence allocation guidelines, encourage policies supporting ex-vivo organ perfusion, and reduce reliance on emergency nighttime surgeries, easing systemic healthcare burdens. The deal also underscores the importance of cross-border collaboration between Japan and Europe in advancing biomedical innovation.
Terumo’s acquisition of OrganOx marks more than a corporate expansion—it is a pivotal moment in transplantation science. By marrying Terumo’s engineering capabilities with OrganOx’s pioneering NMP platform, the collaboration aims to reshape the future of organ preservation. For patients, physicians, and policymakers alike, this integration offers renewed hope that one of medicine’s most pressing shortages—donor organs—may finally be alleviated.
Source: Terumo Corporation Press Release
